The U.S. Food and Drug Administration has approved the first permanently implantable wireless device with remote monitoring to measure pulmonary artery pressure in certain heart failure patients.

The device, manufactured by CardioMEMS Inc. in Atlanta, Ga., remotely measures the pulmonary artery pressures and heart rates of patients with New York Heart Association Class III heart failure who have been hospitalized for heart failure in the previous year. The device can be used at home or other remote locations. Patients with Class III heart failure experience marked limitation in physical activity, even during less-than-ordinary activity such as walking short distances.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access